MA38410A1 - Composés d'azétidinyloxyphénylpyrrolidine - Google Patents

Composés d'azétidinyloxyphénylpyrrolidine

Info

Publication number
MA38410A1
MA38410A1 MA38410A MA38410A MA38410A1 MA 38410 A1 MA38410 A1 MA 38410A1 MA 38410 A MA38410 A MA 38410A MA 38410 A MA38410 A MA 38410A MA 38410 A1 MA38410 A1 MA 38410A1
Authority
MA
Morocco
Prior art keywords
compounds
formula
relates
azetidinyloxyphenylpyrrolidine
azetidinyloxyphenylpyrrolidine compounds
Prior art date
Application number
MA38410A
Other languages
English (en)
Other versions
MA38410B1 (fr
Inventor
Gary G Deng
Danwen Huang
Joshua O Odingo
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA38410A1 publication Critical patent/MA38410A1/fr
Publication of MA38410B1 publication Critical patent/MA38410B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

L'invention concerne certains composés d'azétidinyloxyphénylpyrrolidine, en particulier des composés représentés par la formule i, dans laquelle r désigne hydrogène ou méthyle, ainsi que des compositions pharmaceutiques associées. L'invention concerne également des procédés d'utilisation d'un composé représenté par la formule i pour le traitement de la vessie hyperactive.
MA38410A 2013-03-13 2014-03-07 Composés d'azétidinyloxyphénylpyrrolidine MA38410B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361778546P 2013-03-13 2013-03-13
PCT/US2014/021474 WO2014159012A1 (fr) 2013-03-13 2014-03-07 Composés d'azétidinyloxyphénylpyrrolidine

Publications (2)

Publication Number Publication Date
MA38410A1 true MA38410A1 (fr) 2016-02-29
MA38410B1 MA38410B1 (fr) 2016-09-30

Family

ID=50382705

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38410A MA38410B1 (fr) 2013-03-13 2014-03-07 Composés d'azétidinyloxyphénylpyrrolidine

Country Status (40)

Country Link
US (3) US9034864B2 (fr)
EP (2) EP2970222B1 (fr)
JP (2) JP6017708B2 (fr)
KR (2) KR101702797B1 (fr)
CN (2) CN109336865A (fr)
AP (1) AP3850A (fr)
AR (1) AR095015A1 (fr)
AU (1) AU2014241444B2 (fr)
BR (1) BR112015020222B1 (fr)
CA (1) CA2899806C (fr)
CL (1) CL2015002113A1 (fr)
CR (1) CR20150417A (fr)
CY (1) CY1120142T1 (fr)
DK (1) DK2970222T3 (fr)
DO (1) DOP2015000176A (fr)
EA (1) EA026631B1 (fr)
ES (1) ES2616470T3 (fr)
HK (1) HK1212695A1 (fr)
HR (1) HRP20170080T1 (fr)
HU (1) HUE032235T2 (fr)
IL (1) IL240904B (fr)
JO (1) JO3264B1 (fr)
LT (1) LT2970222T (fr)
MA (1) MA38410B1 (fr)
ME (1) ME02592B (fr)
MX (1) MX2015012579A (fr)
MY (1) MY180006A (fr)
NZ (1) NZ710481A (fr)
PE (1) PE20151669A1 (fr)
PH (1) PH12015502032A1 (fr)
PL (1) PL2970222T3 (fr)
PT (1) PT2970222T (fr)
RS (1) RS55594B1 (fr)
SG (2) SG10201609717YA (fr)
SI (1) SI2970222T1 (fr)
TN (1) TN2015000384A1 (fr)
TW (1) TWI617553B (fr)
UA (1) UA115583C2 (fr)
WO (1) WO2014159012A1 (fr)
ZA (1) ZA201505417B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI617553B (zh) * 2013-03-13 2018-03-11 美國禮來大藥廠 吖丁啶基氧苯基吡咯啶化合物
WO2016033776A1 (fr) * 2014-09-04 2016-03-10 Eli Lilly And Company (2s)-3-[(3s,4s)-3-[(1r)-1-hydroxyéthyl]-4-(4-méthoxy-3-{[1-(5-méthylpyridin-2-yl)azétidin-3-yl]oxy}phényl)-3-méthylpyrrolidin-1-yl]-3-oxopropane-1,2-diol cristallin
TW201625591A (zh) * 2014-09-12 2016-07-16 美國禮來大藥廠 吖丁啶基氧苯基吡咯啶化合物
EP3901146A4 (fr) * 2018-12-18 2022-01-19 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company Composé phénylpyrrolidine et son utilisation
CN111333625B (zh) * 2018-12-18 2022-10-18 武汉人福创新药物研发中心有限公司 苯基吡咯烷类化合物及其用途
CN111333637B (zh) * 2018-12-18 2022-07-29 武汉人福创新药物研发中心有限公司 苯基吡咯烷类衍生物及其制备方法
CN112409333A (zh) * 2019-08-23 2021-02-26 湖北生物医药产业技术研究院有限公司 苯基吡咯烷类化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
JPH07300455A (ja) * 1994-03-08 1995-11-14 Mitsubishi Chem Corp ３−フェニルピロリジン誘導体
DE19601938A1 (de) * 1996-01-12 1997-07-17 Schering Ag Neue Phosphodiesteraseinhibitoren
US6376489B1 (en) * 1999-12-23 2002-04-23 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6258833B1 (en) 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
PL365443A1 (en) * 2001-01-31 2005-01-10 Pfizer Products Inc. Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes
WO2007039075A2 (fr) 2005-09-29 2007-04-12 Bayer Healthcare Ag Inhibiteurs pde et combinaisons de ceux-ci pour traiter des troubles urinaires
TW201206440A (en) 2010-04-28 2012-02-16 Astellas Pharma Inc Prophylactic or therapeutic agent for diseases associated with pains in urinary organs
EP2569302A1 (fr) 2010-05-13 2013-03-20 Amgen, Inc Composés d'hétéroaryloxyhétérocyclyle convenant comme inhibiteurs de la pde10
TWI617553B (zh) * 2013-03-13 2018-03-11 美國禮來大藥廠 吖丁啶基氧苯基吡咯啶化合物

Also Published As

Publication number Publication date
RS55594B1 (sr) 2017-06-30
CN105051034B (zh) 2019-05-21
EA201591498A1 (ru) 2015-12-30
JP2016510759A (ja) 2016-04-11
PL2970222T3 (pl) 2017-06-30
BR112015020222A2 (pt) 2017-07-18
KR20150119077A (ko) 2015-10-23
UA115583C2 (uk) 2017-11-27
AP2015008699A0 (en) 2015-09-30
MY180006A (en) 2020-11-19
WO2014159012A9 (fr) 2014-12-18
EP2970222B1 (fr) 2016-12-21
TW201522327A (zh) 2015-06-16
NZ710481A (en) 2020-08-28
AU2014241444A1 (en) 2015-08-06
EA026631B1 (ru) 2017-04-28
EP3168216A1 (fr) 2017-05-17
ZA201505417B (en) 2022-09-28
CN109336865A (zh) 2019-02-15
CL2015002113A1 (es) 2016-01-15
CA2899806C (fr) 2017-07-18
CA2899806A1 (fr) 2014-10-02
KR20170013411A (ko) 2017-02-06
AP3850A (en) 2016-09-30
AR095015A1 (es) 2015-09-16
US9034864B2 (en) 2015-05-19
PH12015502032A1 (en) 2016-01-18
SG11201507501YA (en) 2015-10-29
TWI617553B (zh) 2018-03-11
ES2616470T3 (es) 2017-06-13
JP6204557B2 (ja) 2017-09-27
AU2014241444B2 (en) 2016-04-07
DOP2015000176A (es) 2015-11-15
US20160122322A1 (en) 2016-05-05
KR101745304B1 (ko) 2017-06-08
HUE032235T2 (en) 2017-09-28
IL240904B (en) 2019-02-28
TN2015000384A1 (en) 2017-01-03
WO2014159012A1 (fr) 2014-10-02
SG10201609717YA (en) 2017-01-27
JP2016216517A (ja) 2016-12-22
JP6017708B2 (ja) 2016-11-02
US9604967B2 (en) 2017-03-28
CR20150417A (es) 2015-09-16
IL240904A0 (en) 2015-10-29
SI2970222T1 (sl) 2017-02-28
LT2970222T (lt) 2017-03-27
ME02592B (fr) 2017-06-20
CN105051034A (zh) 2015-11-11
US9266859B2 (en) 2016-02-23
US20140275002A1 (en) 2014-09-18
HRP20170080T1 (hr) 2017-03-10
HK1212695A1 (zh) 2016-06-17
PE20151669A1 (es) 2015-11-12
MA38410B1 (fr) 2016-09-30
DK2970222T3 (en) 2017-02-27
EP2970222A1 (fr) 2016-01-20
US20150133423A1 (en) 2015-05-14
KR101702797B1 (ko) 2017-02-06
MX2015012579A (es) 2016-01-20
PT2970222T (pt) 2017-02-08
JO3264B1 (ar) 2018-09-16
BR112015020222B1 (pt) 2020-07-14
BR112015020222A8 (pt) 2018-01-23
CY1120142T1 (el) 2018-12-12

Similar Documents

Publication Publication Date Title
MA38410B1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
MA42678B1 (fr) Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
MA41562B1 (fr) Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
MA37519B1 (fr) Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
MA38398B1 (fr) Composés biaryle amides en tant qu'inhibiteurs de kinase
MA38403A1 (fr) Nouveaux dérivés de pyrazole modulateurs specifiques de cb2
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
MA38333A1 (fr) Composés d'azabenzimidazole en tant qu'inhibiteurs d'isozymes pde4 pour le traitement de troubles du snc et d'autres affections
MA38645B1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
MA39152A1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
MA39170A1 (fr) Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
MX370010B (es) Inhibidores de tirosina cinasa de bruton.
MA38250B1 (fr) Nouveau dérivés d'hydantoïne pour leurs utilisations dans le traitement de maladies, comme l'osteoporose et la thrombocytopenie
MA41174B1 (fr) Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
MA39750B1 (fr) Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MA38010B1 (fr) Dérivés d'éthynyl utilisés en tant que modulateurs de l'activité des récepteurs mglur5
MX2016006351A (es) Inhibidores de tirosina cinasa de bruton.
BR112015009988A2 (pt) melhoramentos em compostos orgânicos ou relativos
MA37879B1 (fr) Forme amorphe stabilisée d'agomélatine, procédé pour sa préparation et compositions pharmaceutiques la contenant
MA37685A1 (fr) Composés acide diméthyl-benzoïque inhibiteurs selectifs de l'ep4 pour utilisation dans le traitement d'etats pathologiques inflammatoires tels que l'arthrite
MA38599A1 (fr) Nouveaux dérivés pyrazolopyrrolidine et leur utilisation dans le traitement de maladies